Authors
Faizan Khan, Tobias Tritschler, Miriam Kimpton, Philip S Wells, Clive Kearon, Jeffrey I Weitz, Harry R Büller, Gary E Raskob, Walter Ageno, Francis Couturaud, Paolo Prandoni, Gualtiero Palareti, Cristina Legnani, Paul A Kyrle, Sabine Eichinger, Lisbeth Eischer, Cecilia Becattini, Giancarlo Agnelli, Maria Cristina Vedovati, Geert-Jan Geersing, Toshihiko Takada, Benilde Cosmi, Drahomir Aujesky, Letizia Marconi, Antonio Palla, Sergio Siragusa, Charlotte A Bradbury, Sameer Parpia, Ranjeeta Mallick, Anthonie WA Lensing, Martin Gebel, Michael A Grosso, Kednapa Thavorn, Brian Hutton, Gregoire Le Gal, Dean A Fergusson, Marc A Rodger, MAJESTIC Collaborators
Publication date
2021/10
Source
Annals of internal medicine
Volume
174
Issue
10
Pages
1420-1429
Publisher
American College of Physicians
Description
Background
The long-term risk for major bleeding in patients receiving extended (beyond the initial 3 to 6 months) anticoagulant therapy for a first unprovoked venous thromboembolism (VTE) is uncertain.
Purpose
To determine the incidence of major bleeding during extended anticoagulation of up to 5 years among patients with a first unprovoked VTE, overall, and in clinically important subgroups.
Data Sources
MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials from inception to 23 July 2021.
Study Selection
Randomized controlled trials (RCTs) and prospective cohort studies reporting major bleeding among patients with a first unprovoked VTE who were to receive oral anticoagulation for a minimum of 6 additional months after completing at least 3 months of initial anticoagulant …
Total citations
Scholar articles
F Khan, T Tritschler, M Kimpton, PS Wells, C Kearon… - Annals of internal medicine, 2021